Results 51 to 60 of about 20,923 (159)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. [PDF]
, 2016 Background:
Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with Wanner, Christoph, Inzucchi, SE, Von Eynatten, M, Inzucchi, Silvio E, Lachin, John M, Mattheus, M, Lachin, John M., Zinman, B, Mattheus, Michaela, von Eynatten, Maximilian, Inzucchi, Silvio E., Fitchett, D, Broedl, Uli C., Broedl, UC, Zinman, Bernard, Woerle, Hans J, Wanner, C, Woerle, Hans J., EMPA-REG OUTCOME Investigators,, Johansen, OE, Inzucchi, Silvio, EMPA-REG OUTCOME Investigators, Lachin, JM, Woerle, HJ, Johansen, Odd Erik, Broedl, Uli C, Fitchett, David +26 morecore +2 more sourcesEmpagliflozin and Major Renal Outcomes in Heart Failure
, 2021 Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2.8% of the patients who received empagliflozin and in 3.5% Wanner, Christoph, Jamal, Waheed, Zannad, Faiez, Anker, Filippatos, Gerasimos, Brueckmann, Martina, EMPEROR Study Grp, Zeller, Cordula, Packer, Milton, Butler, Javed, Pocock, Stuart J., Ferreira, Joao P., Stefan D. +12 morecore +1 more sourceEmpagliflozin in type I diabetes
, 2019 There is a clear unmet need in people living with type 1 diabetes (T1D). Although the quality of life of people with T1D has improved, issues like hypoglycemia, weight gain and variability in glucose profiles remain. In this review, the clinical efficacy Van Den Mooter, Laura, Mathieu, Chantal, Eeckhout, Bert +2 morecore +1 more sourceCardiovascular and renal outcomes with empagliflozin in heart failure
, 2020 BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.W de Souza, A Z Maria Middelares, R Velasco Sanchez, G Yang, T Ide, D Kahali, T Kubota, Chuquiure E., I Szakal, J Vaclavik, M Sicer, E De Vuyst, P Fajardo, M Heffernan, V Rastogi, H Bourhaial, Packer M., R A Leon de la Fuente, M Toma, R Bourgeois, M Faghih, Spinar J., M Hartleib, M Ginel, M Seronde, W Kus, C Constance, A Pandey, P Van der Meer, M Manita, J Shin, S von Haehling, C Stellbrink, G Curnew, A Madej, L Yao, N Takahashi, J Amerena, X Jiang, P Wojewoda, Januzzi J., S Verma, Z Sun, J Ascenção de Souza, V Zacà, J Glenny, H Sessa, O Salomone, L Guzman, Y Gonçalves Mello, H Vandekerckhove, T Kadokami, B Lubelsky, H Yamamoto, A Birkenfeld, W Zmuda, A Alvarisqueta, W Fil, L M Backes, Z Yao, G Simon, E Kemala, K Otomo, N Marx, L Maier, M Mansilla, M Licka, T Nakamura, K Oku, H Sekino, T Koga, H Uehara, C P Schulze, J Spyra, T Sydo, D Foldyna, J Sauter, Bohm M., A Bhagwat, M Volpe, Cotton D., A Fernandez, Brunner-La Rocca H. -P., K Nakayama, B Yoo, S Li, S Genth-Zotz, Carson P., A Zhai, J Peruga, Squire I., M Yagi, S Lu, D Piskorz, A Costa-Vitali, H Cho, S Inoue, W König, J Illescas Díaz, Z Vomacka, Y Pan, A Nakata, Y Maruyama, E Swiggum, E R Manenti, F L Gomes, J Almeida Alvarado, A Jobbe Duval, T Nadu, M Kasprzak, A Begemann, S Janssens, C Mazzone, C R Sampaio, M Krol, H Olbrich, A Leone, E Noori, K Maeno, H Urata, M Hernandes, D Babuty, B Shah, J Carrillo Calvillo, J Wong, S Komarlu, Y Kothari, R Isnard, R Chehayeb, L van Heerebeek, M Inoko, M Galinier, G Vervoort, R Bhargava, J Dubois-Rande, M Aguilera Real, Janssens S., Y Sun, A Zurakowski, Sattar N., X Kong, R Campos, D Peng, P Khanoyan, Y Sato, M Ichikawa, I Rodriguez Briones, J Spiegelman, Y Khaykin, J Krupicka, B Krakowiak, Anker S. D., T Matsumoto, K Zeman, J Bono, P Cervinka, K Kawamitsu, N Girerd, F Santos, J Hubac, T Fiala, J Da Silveira, Pina I., S Hwan Han, A Linhart, M Shimizu, J Yan, G Drelich, J López-Sendón, J Berneau, M Dupont, Choi D. -J., P F M M van Bergen, S Kouz, J Jurowiecki, P E Leães, J Ma, O Ludka, M Scherillo, L Pliamm, N Miyagi, G Kania, M Hominal, B Firek, K Radwan, P Dijkmans, D Anauch, Senni M., Y Fukumoto, M Leblanc, L Cartasegna, L A Saliba, D Colquhoun, E Vasconcellos, U Kaul, Merkely B., M Kinoshita, EMPEROR-Reduced Trial Investigators: D Aizenberg, A Fucili, F Cosmi, B Kietselaer, Brueckmann M., W Piesiewicz, D Yung, H Luquez, I C D Westendorp, A Wada, A Salvioni, M Prull, F Fedele, E Hasbani, J Lin, H Darius, X Guo, E A Bocchi, M Koda, M da Consolação Vieira Moreira, R Ahuad Guerrero, R Miklik, N Frey, J Coller, A Begg, E Bonnefoy Cudraz, J Szachniewicz, H Takaishi, Y Kawai, A Hamilton, L Straatman, G Reis, C Alvarez Lorio, A Janik, B Winkelmann, M Suwa, S Nani, M Kujawiak, M Senni, K Yonezawa, J Kim, A Sverdlov, H Ince, S Mazur, A Ogimoto, A Mehta, R Koc, G Raczak, R Preto, G Hiasa, Chopra V., L H Canani, S Tsujiyama, P Michalski, L Valle Molina, G Gonçalves, T Dorsel, O Pereira Dutra, Y Yoshida, L Hill, M Mori, Y Watanabe, G C M Linssen, T Sarens, J Resk, O Jerabek, Giannetti N., Ponikowski P., J F Kerr Saraiva, P Hoogslag, E Lonn, J Zhang, S Taddei, M Nanasato, K Hirabayashi, N Delarche, T Franco Hirakawa, H C Finimundi, T Koizumi, X Han, D Dion, J Cervantes Escárcega, M Rodrigues Bacci, T Saito, A Vorobcsuk, N Giannetti, Zannad F., M V Simões, A Nagy, K Kostner, J Lavoie, H Düngen, Zeller C., H Sugiyama, S Virani, T Hashizume, G Carnero, V Chopra, Y Fujino, Seronde M. -F., P Timmermans, M Cho, H Brunner-La Rocca, M Debinski, M Amuchástegui, S Matsuoka, S Genovese, D Tomasevic, M Oguri, M Alpizar Salaza, M Doi, A Shen, T Smith Casabella, G Llamas Esperon, K Stania, P Debonnaire, B Wozakowska-Kaplon, T Huynh, Y Zhang, C Vieira Nascimento, Taddei S., E Perna, T Shinozaki, D Choi, Gonzalez Juanatey J. R., R Tsunoda, J Berlingieri, A Oomman, B Merkely, W Rieker, S Zieroth, B Lemke, R Peters, J A Ribas Fortes, D Precoma, G Esposito, R Cifkova, Filippatos G., G Habib, Bocchi E., T Barany, M Radvan, H Hori, L Maia, J Alexandre, Y Shibata, C A de Freitas Zerbini, J Jeong, K Fukui, F G Padilla Padilla, Y Momiyama, H Burianova, Y Dong, G Vaddadi, H Fujinaga, A P van Alem, F Villaça Guimarães Filho, T Kataoka, A Ghanem, R van Stralen, S Sakagami, J Grzybowski, J Ye, H Tsuboi, N Al-Windy, H Ebert, J De Sutter, C Zaidman, R Troquay, W Musial, Y Li, W E M Kok, J Yu, J Shankar, F Roubille, S Taguchi, Y Yao, N Kamalakar Ghaisas, J Post, V Vijan, Y Ono, M Najenson, H Colombo, G Skoczylas, V Durdil, R Van de Wal, M van de Wetering, F Picard, P Van De Borne, E Mirek-Bryniarska, D Perez de Arenaza, J Forys, K Cymerman, J Choi, M Hyun Kim, D Kim, D Savard, J Ricci, J Vesely, A Ujeyl, S Min Kang, Z Fan, N Watanabe, A Caccavo, R Groutars, Kaul S., M Berli, K Anderson, Z Zheng, T Yoshitama, Y Kijima, F Lakatos, A Bazzoni Ruiz, B Tyrrell, Jamal W., L Koenyves, P Smits, Wanner C., M Vidotti, Y Furutani, Q Tang, F A Alves da Costa, M Böhm, C Calvo Vargas, M Fernandez Moutin, E Szolnoki, R Gabor Kiss, N Menck, C Poy, J Bauersachs, C Hernandez Herrera, Kimura K., K Kobayashi, Y Kazatani, R Villarreal, Pocock S. J., N Proskynitopoulos, L de la Fuente Galán, C Majul, M Babapulle, L Busak, Y Zheng, F J Neves Mancuso, T Brabec, M M Noya Rabelo, Y Yasaka, J A Kragten, P Podolec, Verma S., V Mehta, I Lopez Alcocer, Zhang J., S Schellong, D Prior, L Beck da Silva Neto, A Yilmaz, S Oishi, B J W M Rensing, L Handoko, Tsutsui H., S Kancz, A Facta, A Kalinka, P Vodnansky, J Oh Na, N Budassi, P Andrassy, M Arikawa, A Takaishi, H Sarnighausen, Butler J., R Prosecky, L Bellersen, A Mullasari, X Xu, M Imamaki, Schnee J., P Miekus, L Lobo Márquez, F Colombo Berra, A Friart, S Yuda, F R den Hartog, P Balsam, Z Yuan, G Skonieczny, Perrone S., N Laszlo, L Noronha, T Himi, A Matoltsy, T Matsunaga, L Danilowicz-Szymanowicz, T Matsumura, F Chenot, K Okuhara, F C Neuenschwander, Nicholls S. J., E Chuquiure Valenzuela, A Wilke +496 morecore +3 more sourcesCardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin
JACC: Basic to Translational Science, 2019 Summary: The positive findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular Outcome Trial of Empagliflozin) on heart failure (HF) outcome in patients with type 2 diabetes mellitus suggest a direct effect of empagliflozin ...Rio P. Juni, PhD, Diederik W.D. Kuster, PhD, Max Goebel, MSc, Michiel Helmes, PhD, René J.P. Musters, PhD, Jolanda van der Velden, PhD, Pieter Koolwijk, PhD, Walter J. Paulus, MD, PhD, Victor W.M. van Hinsbergh, PhD +8 moredoaj +1 more sourceThe Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
MoleculesType 2 diabetes mellitus is a multifactorial disorder whose primary manifestation usually initiates with elevated blood sugar levels. Several antidiabetic agents are used to manage type 2 diabetes mellitus, of which empagliflozin is an oral sodium ...Wael Abu Dayyih, Zainab Zakaraya, Mohammad Hailat, Nafe M. Al-Tawarah, Sahem Alkharabsheh, Haya Khalid Nadher, Zeyad Hailat, Samia M. Alarman, Anas Khaleel, Riad Awad +9 moredoaj +1 more source
